Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store

With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.